Calcarea carbonica induces apoptosis in cancer cells in p53-dependent manner via an immuno-modulatory circuit

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Saha, Shilpi ^a   Hossain, Dewan M S ^a   Mukherjee, Shravanti ^a   Mohanty, Suchismita ^a   Mazumdar, Minakshi ^a   Mukherjee, Sanhita ^b   Ghosh, Uttam K ^a   Nayek, Chaturbhuj ^c   Raveendar, Chinta ^c   Khurana, Anil ^c   Chakrabarty, Rathin ^d   Sa, Gaurisankar ^a   Das, Tanya ^a  

^a BOSE INSTITUTE   (India)

^b CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

^c Central Council for Research in Homeopathy Headquarters   (India)

^d Bholanath Chakrabarty Trust   (India)

Author keywords

Apoptosis; Breast cancer; Calcarea carbonica; Cancer; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CALCAREA CARBONICA; CALCIUM CARBONATE; CASPASE; CYTOCHROME C; CYTOKINE; HOMEOPATHIC AGENT; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; EHRLICH ASCITES TUMOR; EX VIVO STUDY; FLOW CYTOMETRY; HOMEOPATHY; HOST; IMMUNE SYSTEM; IMMUNOMODULATION; MEDICINE; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; T LYMPHOCYTE; TUMOR REGRESSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CALCIUM CARBONATE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; MICE; MITOCHONDRIA; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884302478     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-230     Document Type: Article

References (53)

1. Siegel R, DeSantis G, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012, 62:220-241. 10.3322/caac.21149, 22700443.
2. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004, 22:2233-2239. 10.1200/JCO.2004.08.094, 15169812.
3. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008, 12:1-23.
4. Johannessen H, Hjelmborg J, Pasquarelli E, Fiorentini G, Di Costanzos F, Miccinesi G. Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori 2008, 94:406-410.
5. Trager-Maury S, Tournigand C, Maindrault-Goebel F, Afchain P, De Gramont A, Garcia-Larnicol ML, Gervais H, Louvet C. Use of complementary medicine by cancer patients in a French oncology department. Bull Cancer 2007, 94:1017-1025.
6. Flinn JE. Bromium in acute lymphatic leukemia. J Am Inst Homeopath 1965, 58:213-214.
7. Preethi KC, Kuttan G, Kuttan R. Anti-tumour activity of rutagraveolens extract. Asian Pac J Cancer Prev 2006, 7:439-443.
8. Sur RK, Samajdar K, Mitra S, Gole MK, Chakrabarty BM. Hepatoprotective action of potentized lycopodium clavatum L. Br Homeopath J 1990, 79:152-156.
9. Frenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, Leblanc A, Cohen L, Banerji P, Banerji P. Cytotoxic effects of ultra-diluted remedies on breast cancer cells. Int J Oncol 2010, 36:395-403.
10. MacLaughlin BW, Gutsmuths B, Pretner E, Jonas WB, Ives J, Kulawardane DV, Amri H. Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr Cancer Ther 2006, 5:362-372.
11. Guimarães FS, Andrade LF, Martins ST, Abud AP, Sene RV, Wanderer C, Tiscornia I, Bollati-Fogolín M, Buchi DF, Trindade ES. In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model. BMC Cancer 2010, 10:113. 10.1186/1471-2407-10-113, 2859384, 20338038.
12. Sa G, Das T, Moon C, Hilston CM, Rayman PA, Rini BI, Tannenbaum CS, Finke JH. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009, 69:3095-3104. 2728031, 19276353.
13. Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, Rayman P, Kudo D, Biswas K, Bukowski RM, Finke JH, Tannenbaum CS. Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways. J Immunol 2008, 180:4687-4696.
14. Das T, Sa G, Hilston C, Kudo D, Rayman P, Biswas K, Molto L, Bukowski R, Rini B, Finke JH, Tannenbaum C. GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res 2008, 68:2014-2023. 10.1158/0008-5472.CAN-07-6037, 18339884.
15. Chattopadhyay S, Bhattacharyya S, Saha B, Chakraborty J, Mohanty S, Sakib Hossain DM, Banerjee S, Das K, Sa G, Das T. Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins. PLoS One 2009, 4:e7382. 10.1371/journal.pone.0007382, 2753647, 19812686.
16. Bhattacharyya S, Md Sakib Hossain D, Mohanty S, Sankar Sen G, Chattopadhyay S, Banerjee S, Chakraborty J, Das K, Sarkar D, Das T, Sa G. Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 2010, 7:306-315. 10.1038/cmi.2010.11, 20305684.
17. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G. Curcumin prevents tumor-induced T cell apoptosis through stat-5a-mediated Bcl-2 induction. J Biol Chem 2007, 282:15954-15964. 10.1074/jbc.M608189200, 17392282.
18. Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, Lahiry L, Finke JH, Tannenbaum CS, Das T, Sa G. Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: protection by curcumin. Cancer Res 2007, 67:362-370. 10.1158/0008-5472.CAN-06-2583, 17210719.
19. Mandal D, Lahiry L, Bhattacharyya A, Bhattacharyya S, Sa G, Das T. Tumor-induced thymic involution via inhibition of IL-7R alpha and its JAK-STAT signaling pathway: protection by black tea. Int Immunopharmacol 2006, 6:433-444. 10.1016/j.intimp.2005.09.005, 16428079.
20. Mandal D, Bhattacharyya S, Lahiry L, Chattopadhyay S, Sa G, Das T. Black tea-induced decrease in IL-10 and TGF-beta of tumor cells promotes Th1/Tc1 response in tumor bearer. Nutr Cancer 2007, 58:213-221. 10.1080/01635580701328503, 17640168.
21. Das T, Sa G, Chattopadhyay S, Ray PK. Protein a-induced apoptosis of cancer cells is effected by soluble immune mediators. Cancer Immunol Immunother 2002, 51:376-380. 10.1007/s00262-002-0288-0, 12192537.
22. Guimaraes FSF, Abud AP, Oliveira SM, Oliveira CC, César B, Donatti L, Gabardo J, Trindade ES, Buchi DF. Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication. BMC Cancer 2009, 9:293. 10.1186/1471-2407-9-293, 2749867, 19698142.
23. Klein G, Sjigren HO, Klein E, Hellstorm KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960, 20:1561-1572.
24. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007, 179:5845-5854. 2140228, 17947658.
25. Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007, 19:301-308. 10.1016/j.coi.2007.04.011, 17433871.
26. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2:735-747. 10.1038/nri911, 12360212.
27. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20:323-370. 10.1146/annurev.immunol.20.100201.131730, 11861606.
28. Thiery J, Dorothee G, Haddada H, Echchakir H, Richon C, Stancou R, Vergnon I, Benard J, Mami-Chouaib F, Chouaib S. Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J Immunol 2003, 170:5919-5926.
29. Dorothee G, Ameyar M, Bettaieb A, Vergnon I, Echchakir H, Bouziane M, Chouaib S, Mami-Chouaib F. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells. Int J Cancer 2001, 91:772-777. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1132>3.0.CO;2-V, 11275978.
30. Kawasaki Y, Saito T, Shirota-Someya Y, Ikegami Y, Komano H, Lee MH, Froelich CJ, Shinohara N, Takayama H. Cell death-associated translocation of plasma membrane components induced by CTL. J Immunol 2000, 164:4641-4648.
31. Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, Banerjee S, Choudhuri T, Mandal D, Bhattacharyya A, Sa G, Das T. Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis 2008, 13:771-781. 10.1007/s10495-008-0213-x, 18454316.
32. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1 expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005, 280:20059-20068. 10.1074/jbc.M410670200, 15738001.
33. Chakraborty J, Banerjee S, Ray P, Hossain DM, Bhattacharyya S, Adhikary A, Chattopadhyay S, Das T, Sa G. Gain of cellular adaptation due to prolong p53 impairment leads to functional switch-over from p53 to p73 during DNA damage in acute myeloid leukemia cells. J Biol Chem 2010, 285:33104-33112. 10.1074/jbc.M110.122705, 2963387, 20675383.
34. Adhikary A, Mohanty S, Lahiry L, Hossain DM, Chakraborty S, Das T. Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett 2010, 584:7-14. 10.1016/j.febslet.2009.10.081, 19883646.
35. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001, 20:7779-7786. 10.1038/sj.onc.1204984, 11753656.
36. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 2011, 68:1161-1172. [Epub ahead of print], 10.1007/s00280-011-1596-x, 21400027.
37. Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S. Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 2009, 187:40-44. 10.1016/j.toxlet.2009.01.025, 19429242.
38. Hebishima T, Matsumoto Y, Watanabe G, Soma G, Kohchi C, Taya K, Hayashi Y, Hirota Y. Protective effects of the immunopotentiator from Pantoeaagglomerans 1 on chemotherapeutic agent-induced macrophage growth inhibition. Anticancer Res 2010, 30:2033-2040.
39. Seligmann IC, Lima PD, Cardoso PC, Khayat AS, Bahia MO, Buchi Dde F, Cabral IR, Burbano RR. The anticancer homeopathic composite "Canova method" is not genotoxic for human lymphocytes in vitro. Genet Mol Res 2003, 30:223-228.
40. Hana G, Bar-Sela G, Zhana D, Mashiach T, Robinson E. The use of complementary and alternative therapies by cancer patients in northern Israel. Isr Med Assoc J 2005, 7:243-247.
41. Han SB, Lee CW, Kang MR, Yoon YD, Kang JS, Lee KH, Yoon WK, Lee K, Park SK, Kim HM. Pectic polysaccharide isolated from Angelica gigas Nakai inhibits melanoma cell metastasis and growth by directly preventing cell adhesion and activating host immune functions. Cancer Lett 2006, 243:264-273. 10.1016/j.canlet.2005.11.040, 16412568.
42. Wälchli C, Baumgartner S, Bastide M. Effect of low doses and high homeopathic potencies in normal and cancerous human lymphocytes: an in vitro isopathic study. J Altern Complement Med 2006, 12:421-427. 10.1089/acm.2006.12.421, 16813505.
43. De Oliveira CC, Ana PR A, De Oliveira SM, et al. Developments on drug discovery and on new therapeutics: highly diluted tinctures act as biological response modifiers. BMC Complement Altern Med 2011, 11:101. 10.1186/1472-6882-11-101, 3222609, 22029602.
44. Sato DY, Wal R, Oliveira CC, Cattaneo RI, Malvezzi M, Gabardo J, Buchi DF. Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a Brazilian homeopathic medication. Homeopathy 2005, 94:26-32. 10.1016/j.homp.2004.10.003, 15751331.
45. Pascual-Carpe F, Vicente-Ortega V, Campos-Aranda M, Yañez-Gascón J. In vivo treatment of melanoma (B16F10) with a homeopathic agent and with a cytokine (IFN-α). Oncol Res 2006, 16:211-216.
46. Es S, Kuttan G, Kc P, Kuttan R. Effect of homeopathic medicines on transplanted tumors in mice. Asian Pac J Cancer Prev 2007, 8:390-394.
47. Xie Y, Bai O, Yuan J, Chibbar R, Slattery K, Wei Y, Deng Y, Xiang J. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses. Cancer Res 2009, 69:7756-7766. 10.1158/0008-5472.CAN-09-0496, 19789353.
48. Seligmann IC, Lima PD, Cardoso PC, Khayat AS, Bahia MO, Buchi De F, CabralI R, Burbano RR. The anticancer homeopathic composite "Canova method" is not genotoxic for human lymphocytes in vitro. Genet Mol Res 2003, 2:223-238.
49. Qu P, Yan C, Du H. Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood 2011, 117:4476-4489. [Epub ahead of print], 10.1182/blood-2010-07-298380, 3099569, 21378275.
50. Wang H, Xie X, Lu WG, Ye DF, Chen HZ, Li X, Cheng Q. Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK-STAT signaling pathway. Life Sci 2004, 74:1739-1749. 10.1016/j.lfs.2003.07.051, 14741732.
51. Wang Y, Da'Dara AA, Thomas PG, Harn DA. Dendritic cells activated by an anti-inflammatory agent induce CD4+ T helper type 2 responses without impairing CD8+ memory and effector cytotoxic T-lymphocyte responses. Immunology 2010, 129:406-417. 10.1111/j.1365-2567.2009.03193.x, 2826685, 19922421.
52. Pallis M, Grundy M, Turzanski J, Kofler R, Russell N. Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. Blood 2001, 98:405-413. 10.1182/blood.V98.2.405, 11435310.
53. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-811. 10.1038/sj.onc.1209608, 16892092.